Linthorst GE - Search Results

1

Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients.

Hollak CE, de Sonnaville ES, Cassiman D, Linthorst GE, Groener JE, Morava E, Wevers RA, Mannens M, Aerts JM, Meersseman W, Akkerman E, Niezen-Koning KE, Mulder MF, Visser G, Wijburg FA, Lefeber D, Poorthuis BJ. Hollak CE, et al. Among authors: linthorst ge. Mol Genet Metab. 2012 Nov;107(3):526-33. doi: 10.1016/j.ymgme.2012.06.015. Epub 2012 Jun 30. Mol Genet Metab. 2012. PMID: 22818240

2

Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort.

Arends M, Linthorst GE, Hollak CE, Biegstraaten M. Arends M, et al. Among authors: linthorst ge. Mol Genet Metab. 2016 Feb;117(2):194-8. doi: 10.1016/j.ymgme.2015.11.014. Epub 2015 Dec 1. Mol Genet Metab. 2016. PMID: 26654842

3

Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.

Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT, Scheij S, Aerts JM. Vedder AC, et al. Among authors: linthorst ge. Mol Genet Metab. 2006 Nov;89(3):239-44. doi: 10.1016/j.ymgme.2006.04.013. Epub 2006 Jun 9. Mol Genet Metab. 2006. PMID: 16765076 Clinical Trial.

4

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

Hollak CE, Linthorst GE. Hollak CE, et al. Among authors: linthorst ge. Mol Genet Metab. 2009 Jan;96(1):1-3. doi: 10.1016/j.ymgme.2008.10.013. Epub 2008 Dec 4. Mol Genet Metab. 2009. PMID: 19062323 No abstract available.

5

Vasculopathy in patients with Fabry disease: current controversies and research directions.

Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Rombach SM, et al. Among authors: linthorst ge. Mol Genet Metab. 2010 Feb;99(2):99-108. doi: 10.1016/j.ymgme.2009.10.004. Epub 2009 Oct 13. Mol Genet Metab. 2010. PMID: 19900828

6

A revised home treatment algorithm for Fabry disease: influence of antibody formation.

Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. Smid BE, et al. Among authors: linthorst ge. Mol Genet Metab. 2013 Feb;108(2):132-7. doi: 10.1016/j.ymgme.2012.12.005. Epub 2012 Dec 28. Mol Genet Metab. 2013. PMID: 23332169

7

Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency).

Linthorst GE, Folman CC, Aerts JM, Hollak CE. Linthorst GE, et al. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):324-6. doi: 10.1016/s1079-9796(03)00163-3. Blood Cells Mol Dis. 2003. PMID: 14636646

8

Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.

Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE. Linthorst GE, et al. Nephrol Dial Transplant. 2006 Feb;21(2):355-60. doi: 10.1093/ndt/gfi221. Epub 2005 Oct 25. Nephrol Dial Transplant. 2006. PMID: 16249196

9

Novel therapeutic targets for the treatment of Fabry disease.

Hollak CE, Vedder AC, Linthorst GE, Aerts JM. Hollak CE, et al. Among authors: linthorst ge. Expert Opin Ther Targets. 2007 Jun;11(6):821-33. doi: 10.1517/14728222.11.6.821. Expert Opin Ther Targets. 2007. PMID: 17504019 Review.

10

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mehta A; European Medicines Agency. Linthorst GE, et al. Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30. Mol Genet Metab. 2011. PMID: 21123099

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

104 results

Search Page